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INTRODUCTION
Intramedullary spinal cord tumors (IMSCTs) possess approxi-
mately 4–10% of all central nervous system (CNS) tumors.1,2 
Surgery is the main treatment method for IMSCTs; however, 
the involvement of neural tracts in IMSCTs makes it difficult to 
completely cure them by surgery.3,4 Recently, radiotherapy or 
chemotherapy after surgery are being considered as external 
modes of therapy for IMCSTs. A multi-disciplinary mode of 
treatment, involving maximal surgical resection along with ra-
diotherapy-combined temozolomide, allows the patients to ex-
perience an average survival time of less than 2 years.5,6
Many studies have reported that combination treatments, 
such as chemotherapy, gene therapy, or radiotherapy display, 
improved the anti-cancer efficacy of glioblastomas in the spi-
nal cord or the brain.7,8 Currently, the application of combina-
tion therapy using an anti-angiogenic agent and chemothera-
py has been found to show higher therapeutic efficacy in the 
treatment of brain glioblastoma compared to any single mode 
of therapy alone.4,9 Bevacizumab is a monoclonal antibody 
that serves as an anti-angiogenic agent by targeting the vascu-
lar endothelial growth factor (VEGF) and inhibiting angiogen-
esis.10 It has been approved by the FDA as a first-line treatment 
for combination therapy of cancer.11 Pre-clinical evidence and 
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attie and Bresnahan scale scores for all of the treatment groups were recorded every other day for 15 days to assess the rat hind-
limb strength. 
Results: The complexes of bPEI/pEpo-NI2-SV-TK inhibited the viability of C6 cells in the hypoxia condition at 5 days after treat-
ment with ganciclovir. Bevacizumab was decreased in the cell viability of human umbilical vein endothelial cells. Combination 
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clinical trials have confirmed that bevacizumab inhibits tumor 
progression by targeting abnormal tumor vessels.12,13 Bevaci-
zumab therapy causes devascularization and hypoxia-like con-
ditions in tumors.12
Tissue-specific gene delivery systems have been developed 
to increase the efficacy and safety by inducing protein expres-
sion after gene delivery and minimizing damage to normal 
cells.14 The glioma dual-specific TK gene increases the thera-
peutic efficacy in brain tumor tissues without side effect.15,16 
Transcription regulation has been investigated using tissue-
specific promoters, such as the glial fibrillary acidic protein 
(GFAP) promoter or nestin intron 2 (NI2).17,18 Kim, et al.15 re-
ported that the use of Epo enhancer with NI2 dual-specific 
herpes simplex virus thymidine kinase gene (HSV-TK) and 
ganciclovir (GCV) is a powerful gene therapy strategy for malig-
nant gliomas.19 The solid tumor-like glioblastoma grows rapid-
ly, leading to a lack of blood supply.20,21 This results in a signifi-
cantly low oxygen concentration in the tumor compared to the 
normal tissue, due to the rapid proliferation of tumor cells and 
the limited amount of oxygen available to diffuse into the tumor 
tissue.22 Previous studies have shown that the Epo enhancer 
increases gene expression in glioblastoma under the condi-
tion of hypoxia, while NI2 induces gene expression in neural 
stem cells or glioblastoma.23-25 In this study, we developed a 
novel therapy using a combination of bevacizumab, hypoxia, 
and the glioma dual-specific gene, pEpo-NI2-SV-TK, for the 
treatment of IMSCTs. We investigated whether a combination 
therapy involving bevacizumab and pEpo-NI2-SV-TK has en-




The plasmids, pEpo-NI2-SV-Luci and pEpo-NI2-SV-TK, were 
constructed with the elements, Epo enhancer, NI2, and pSV-
HSV-TK, as described previously.15 All of the plasmids used in 
this study, including pSV-Luci (Promega, Madison, WI, USA), 
were provided by Professor Minhyung Lee. The plasmids were 
transformed into Escherichia coli DH5-α (RBC, Taipei, Tai-
wan) and cultured in Luria-Bertani broth medium containing 
50 μg/mL ampicillin at 37°C overnight with continuous shak-
ing at 250 rpm. The amplified plasmids were purified using 
the Endofree Maxi plasmid purification kit (Qiagen, Venlo, the 
Netherlands), according to the manufacturer’s instructions. The 
plasmid DNA (pDNA) was quantified using a Nanodrop spec-
trophotometer (ND-1000, Thermo Fisher Scientific, Waltham, 
MA, USA) at a wavelength of 260 nm.
Cell culture
C6 (rat glioma) cells and human embryonic kidney (HEK 293) 
cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco, Grand Island, NY, USA) supplemented with 
10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 
1% penicillin/streptomycin (Gibco). To establish stable DsRed-
expressing C6 cells, the complexes of the pBudCE4.1-DsRed 
plasmid with lipofectamine (Invitrogen, Carlsbad, CA, USA) 
were transfected into C6 cells, according to a previously de-
scribed protocol.4 The DsRed-expressing cells were selected 
using Zeocin (Invitrogen). Human umbilical vein endothelial 
cells (HUVECs) were maintained in endothelial cell basal me-
dium supplemented with endothelial cell growth medium 
(EGM-2) Bulletkit (Lonza, Walkersville, MD, USA) on culture 
dishes coated with 1 μg/cm2 human fibronectin (Sigma, St. 
Louis, MO, USA). The culture medium was replaced every oth-
er day.
Measurement of transfection efficiency and luciferase 
assay for the dual-specific gene
C6 and HEK 293 cells were plated into 6-well plates at a densi-
ty of 2×105 cells/well and cultured overnight. Complexes of 
branched polyethylenimine (bPEI) (molecular weight: 25000 
Da, Sigma) and the various pDNAs were prepared with an N/
P ratio of 5, according to previous reports.26 Before transfec-
tion, the medium was replaced with serum-free DMEM. The 
bPEI/pDNA complexes were added to each well at a dosage 
of 2 µg pDNA/well, and the cells were incubated for 4 h. After 
the 4-h incubation, the medium was replaced with a fresh 
medium containing 10% FBS. The cells were incubated for an 
additional 44 h under the conditions of hypoxia (1% O2) or 
normoxia (20% O2). To evaluate the luciferase expression, lu-
ciferase activity was measured using the Promega Luciferase 
Assay System, in accordance with the manufacturer’s protocol 
(Promega). Cells were washed with phosphate buffered saline 
(PBS) and then homogenized using 1x Reporter Lysis Buffer 
(Promega). The lysates were then incubated for 1 h on ice, fol-
lowed by centrifugation at 13000×g for 10 min. The transfection 
efficiency of the various pDNAs was measured using a Versa-
Max enzyme-linked immunosorbent assay (ELISA) microplate 
reader (Molecular Devices, Sunnyvale, CA, USA). The total 
protein content in the supernatants was determined using a 
bicinchoninic acid protein assay kit (Pierce Biotechnology, 
Rockford, IL, USA). Luciferase activity has been expressed as 
relative light units/mg protein.
In vitro effects of the dual-specific TK gene and GCV
To evaluate the effects of the dual-specific TK gene and GCV, 
the complexes of bPEI with pSV-TK or pEpo-NI2-TK were pre-
pared with an N/P ratio of 5. C6 cells were plated into 12-well 
plates at a density of 5×104 cells/well and cultured for 24 h. 
The bPEI complexes were added to each well and incubated 
with the cells for 4 h. After incubation, the medium was re-
placed with fresh DMEM medium containing 10% FBS and 10 
µg/mL GCV. The cells were then incubated for 2 or 5 days un-
der hypoxic conditions.
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In vitro effects of bevacizumab
The effects of bevacizumab were determined by measuring 
the mitochondrial metabolic activity of C6 cells and HUVECs 
treated with various concentrations of bevacizumab (Avastin, 
Roche, Basel, Switzerland) using an 4.1. 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. C6 
cells and HUVECs were plated in 96-well plates at a density of 
2×104 cells/well and cultured overnight. Various concentrations 
of bevacizumab (Roche Korea Co. Ltd., Seoul, Korea) were add-
ed to each respective well of the plates. After incubation for 3 
days at 37°C, the cultured cells were rinsed with PBS, and 200 
µL MTT (Thiazolyl Blue Tetrazolium Bromide, Sigma-Aldrich, 
2 mg/mL in media, Sigma) was added to the cells. The plates 
were incubated for an additional 4 h at 37°C, after which the 
MTT solution was removed. The resulting insoluble particles 
were dissolved in 100 µL dimethyl sulfoxide Hybri-maxTM (Sig-
ma) for 30 min to dissolve the formazan crystals, followed by 
the measurement of absorbance at a wavelength of 540 nm us-
ing an ELISA plate reader.
Anti-cancer efficacy of bevacizumab and dual-specific 
TK gene in a spinal cord tumor model
The Animal Care and Use Committee of the Medical Research 
Institute of Yonsei University College of Medicine approved 
all of the protocols used in this study. Experiments were per-
formed according to the international guidelines on ethical 
use of animals; minimal number of animals was used in this 
study. Spinal cord tumors were generated in adult male Sprague 
Dawley rats (250–300 g; n=28, Orient Bio, Seongnam, Korea) 
as described below. Sprague Dawley rat were anesthetized us-
ing Zoletil (30 mg/kg, Virbac, Carros, France), and an incision 
was made over the dorsal T6 level. After that, laminectomy 
was performed at the T5 level using an orthopedic bone cut-
ter, and 1×105 C6 glioma cells dissolved in 3 µL PBS were in-
jected into the T5 position using a Hamilton syringe (Hamilton, 
Bonaduz, Switzerland). Five days after the injection of C6 cells, 
the rats were randomly assigned to four experimental groups 
(n=7 for each group). The control group received an injection 
of 10 μL serum-free medium at the same injection site as the 
C6 cells. The TK alone group was injected with the complexes 
of 10 μg bPEI+pEpo-NI2-TK at the tumor site, followed by an 
intraperitoneal (I.P.) injection of 40 mg/kg GCV every day for 
the next 10 days. The bevacizumab alone group was given an 
I.P. injection of 7 mg/kg bevacizumab every other day for the 
next 10 days. The combination therapy group was given an I.P. 
injection of 10 μg bPEI/pEpo-NI2-TK complexes at the same 
injection site as the C6 cells, followed by I.P. injections of 40 
mg/kg GCV every day and 7 mg/kg bevacizumab every other 
day for the next 10 days.
Histological analysis and functional tests
Rat hind-limb strength was assessed using the Basso, Beattie 
and Bresnahan (BBB) scale.27 The BBB locomotor scale has a 
wide range of evaluation for hindlimb movement, plantar step-
ping, coordinated limb movement, toe clearance, parallel paw 
position throughout the stem cycle, and tail consistently up. 
The BBB scores for all of the rats were tested pre-operatively to 
ensure a baseline locomotor rating of 21. The BBB score of 0 in-
dicated no observable hindlimb movement after spinal cord 
injury. 
Rats were placed in an open field testing area, allowed to 
adaptm and then observed for 5 min. After the operation, the 
BBB scores for all treatment groups were recorded every other 
day for 15 days. After the final injection, the rats were sacri-
ficed and perfused with saline containing 4% paraformalde-
hyde (Merck, Frankfurt, Germany). The tumor regions were 
dissected and sectioned to a thickness of 10 µm for histological 
analyses. The sections were processed for standard hematoxy-
lin and eosin (H&E) staining. To evaluate the effect of the dual-
specific TK gene in spinal cord tumors, the sections prepared 
from areas that were approximately 0.5 mm and 1 mm lateral to 
the tumor injection site were observed by H&E staining.
Magnetic resonance imaging (MRI)
MRI was performed four times for each spinal cord tissue 
sample. For the detection of tumors, MRI was conducted using 
a Bruker 9.4T BioSpec scanner (Bruker Corporation, Ettlingen, 
Germany). A transverse T2-weighted RARE sequence with the 
following parameters was used: repetition time/effective echo 
time, 2000/9 ms; RARE factor, 2; in-plane resolution, 0.156× 
0.156 mm; slice thickness, 0.5 mm.
Statistical analysis
Quantitative data were expressed as the mean±standard devi-
ation. Statistically analysis was performed by one-way ANOVA 
with the least significant difference method. Student’s t-test was 
used to perform post-hoc comparisons of the sub-groups. All 
statistical analyses were performed using the SPSS software 
(version 21; IBM Corp., Armonk, NY, USA), and p-values less 
than 0.05 were considered statistically significant.
RESULTS
Transfection efficacy of dual-specific plasmid
To evaluate the effect of the glioma-hypoxia dual-specific gene, 
bPEI/pEpo-NI2-SV-Luci complexes were transfected into C6 
glioma cells and HEK 293 cells under the conditions of nor-
moxia or hypoxia. As a control, bPEI/pSV-Luci complexes were 
also transfected into the C6 glioma cells. In C6 cells, the lucifer-
ase activity of bPEI/pEpo-NI2-SV-Luci complexes was found 
to increase in the conditions of both normoxia and hypoxia. 
The luciferase activity of the bPEI/pEpo-NI2-SV-Luci complex-
es was approximately four times higher in hypoxia compared 
to normoxia (Fig. 1A). However, the luciferase activity of the 
bPEI/pSV-Luci complexes was not significantly different in 
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the normoxia and hypoxia conditions. In contrast, in HEK 293 
cells, there was no significant difference in the luciferase ac-
tivity of the bPEI+pEpo-NI2-SV-Luci complex under normox-
ia and hypoxia (Fig. 1B). The bPEI/pEPO-NI2-SV-Luci com-
plexes significantly induced the luciferase expression in C6 
cells. These results showed that the plasmid pEpo-NI2-SV-Lu-
ci causes increased gene expression under hypoxia, and this 
effect is specific to the cell type.
Effects of dual-specific TK gene in hypoxia condition
To optimize the amount of GCV treatment after the transfection 
of bPEI/pEpo-NI2-SV-TK complexes into glioma, we evaluated 
the cell viability 2 days after treatment with various concentra-
tions of GCV using an MTT assay. The cell proliferation rate of 
C6 cells treated with 80 µg/mL GCV was not significantly dif-
ferent from those treated with 10 µg/mL GCV (Fig. 2A). To de-
termine whether the glioma and hypoxia-specific effects of 
the TK gene were dependent on the concentration of GCV, we 
transfected the bPEI/pEpo-NI2-SV-TK complexes into C6 gli-
oma cells and incubated them with various concentrations of 
GCV for 5 days under the conditions of hypoxia and normox-
ia. At the end of 5 days, cell viability in the groups treated with 
bPEI/pEpo-NI2-SV-TK complexes were found to be significant-
ly different under hypoxia and normoxia conditions. In addi-
tion, the cell viability was found to decrease with an increase 
in GCV concentration (Fig. 2B).
Fig. 2. Cell viability, as measured by MTT assay, after transfection of bPEI/NI2-SV-TK complexes into C6 cells followed by GCV treatment. (A) C6 cell viabil-
ity after treatment with various concentrations of GCV and (B) cell viability at 2 or 5 days after transfection with bPEI/NI2-SV-TK complexes followed by 
GCV treatment under the condition of hypoxia. *p<0.05 compared to the group not treated with GCV. MTT, 4.1. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tet-
razolium bromide; bPEI, branched polyethylenimine; GCV, ganciclovir.
Fig. 1. Dual-specific gene expression of luciferase gene by bPEI/Epo-NI2-SV-Luci. The bPEI/pSV-Luci and bPEI/pEpo-NI2-SV-Luci were transfected into 
(A) C6 cells and (B) HEK 293 cells. The cells were incubated for 2 days under normoxic or hypoxic conditions and assessed for luciferase activity. The 
data are expressed as the mean±standard deviation of six independent experiments. *p<0.05 compared to the normoxia group. bPEI, branched polyeth-










































































10             20             40             60             80            160 0                 10                 20                 40                 60                80               160

























Combination Therapy in Spinal Cord Tumor 
https://doi.org/10.3349/ymj.2020.61.12.1042
Effect of bevacizumab on C6 glioma cells and HUVECs
We evaluated the effects of various concentrations of bevaci-
zumab on the cytotoxicity of C6 cells and HUVECs using MTT 
assay. C6 glioma cells and HUVECs were treated with bevaci-
zumab for 5 days. Bevacizumab is an angiogenesis inhibitor 
and reduces HUVEC proliferation.13 Five days after treatment 
with varying concentrations of bevacizumab, there was no in-
hibition in the proliferation of C6 cells (Fig. 3A). In contrast, in 
HUVECs, there was a significant decrease in the cell viability 
rate in the group treated with 50 μM bevacizumab compared 
to the untreated control group (p<0.05) (Fig. 3B).
Effects of treatment with TK gene with GCV and 
Bevacizumab on spinal cord tumors
The anti-cancer effects of the combination therapy were evalu-
ated 15 days after the injection of C6 cells into the spinal cord 
by measuring the hind-limb function. Hind-limb function 
was evaluated every other day for 15 days after the injection of 
C6 glioma cells. The median hind-limb BBB score for the four 
groups was 18 at 5 days post-injection of C6 glioma cells (Fig. 
4). The BBB score of the control group started to decline on Day 
9, and reached 5.2 on Day 15. The BBB score of the bPEI/pSV-
TK complexes-treated group began to decline on Day 9 and 
reached approximately 8 on Day 15, while the BBB score of the 
bevacizumab-treated group started declining on Day 9 and 
reached approximately 10 on Day 15. 
The anti-cancer effects of the various test treatments were 
also evaluated by performing histological analyses and MRI of 
the tumor area 15 days post-injection of the C6 cells (Fig. 5). 
Histological analyses showed the tumor area in the T5 region. 
Fig. 5 shows representative images of H&E-stained sections of 
spinal cord tumors from the various animal groups and la-
beled C6 cells in the spinal cord. We observed fewer labeled C6 
cells in the spinal cord from the combination-treated group 
compared to other groups. The combined treatment with beva-
cizumab and dual-specific TK gene significantly reduced the tu-
mor area compared to other treatments (Fig. 5). In the control 
group, nearly the entire area of the spinal cord was covered 
with the tumor. Compared to the control group, the groups 
treated with bevacizumab alone or the dual-specific TK gene 
alone showed greater inhibition of tumor growth in the spinal 
cord. The sagittal view of MRI indicated that the combined ther-
apy of bevacizumab and dual-specific pTK gene inhibits IM-
SCT much more efficiently than treatment by bevacizumab or 
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Fig. 4. Functional test of hind-limb strength. Hind-limb function was as-
sessed using the BBB score every other day for 15 days after C6 glioma 
cell injection into the spinal cord. *p<0.05 combination therapy group com-
pared to bPEI/pEpo-NI2-SV-TK complex-treated group at 13 days and 15 
days. BBB, Basso, Beattie and Bresnahan; bPEI, branched polyethyleni-
mine.
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DISCUSSION
The current treatment methods for IMSCTs includes surgery, 
chemotherapy, and radiotherapy.28,29 Recently, clinical advanc-
es in multi-modality treatment, such as chemotherapy com-
bined with radiotherapy, have led to an increase in the survival 
rate of patients with IMSCTs.30 In addition to these methods, 
gene therapy has been explored as a possible alternative ap-
proach to overcome IMSCTs.31 This study showed that treat-
ment using a combination of gene therapy and bevacizumab 
reduced the growth of spinal cord tumors with greater efficacy 
compared to using any treatment alone.
Combination treatment involving both dual-specific TK 
gene and bevacizumab inhibited the growth of tumor. Oh, et 
al.16 reported that combination therapy involving both glioblas-
toma-specific TK gene/R7L10 with bevacizumab to treat brain 
tumor reduced the tumor volume by approximately 50%. 






































Fig. 5. Assessment of tumor size in the spinal cord after treatment. (A) H&E staining of IMSCT sections 10 days post-treatment with complexes and beva-
cizumab. The dotted yellow lines indicate the IMSCT area. (B) Photomicrographs of DsRed-expressing C6 glioma cells (red) in the spinal cord. Blue color 
indicates the spinal cord. Scale bar: 500 μm. The area occupied by DsRed-expressing cells was smaller in the combination treatment group than in the oth-
er groups. (C) Tumor area in spinal cord by cross section. (D) MRI analysis of IMSCTs. *p<0.05 combination therapy group compared to bPEI/pEpo-NI2-SV-
TK complex-treated group, bevacizumab and control. H&E, hematoxylin and eosin; DAPI, 4,6-diamidino-2-phenylindole; IMSCTs, intramedullary spinal 
cord tumors; MRI, magnetic resonance imaging; bPEI, branched polyethylenimine.
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sition factor siRNA and VEGF siRNA for the reduction of VEGF 
expression decelerated cell growth more efficiently as com-
pared to siRNA transfection alone.32 Here, we evaluated the 
anti-tumor effects of combination therapy of hypoxia-glioma 
dual-specific TK gene and bevacizumab in rat spinal cord tu-
mors. Combination therapy of bPEI/dual specific TK gene and 
bevacizumab caused a slow decline in the hind-limb BBB scores 
and an approximately 2-fold decrease in the tumor area com-
pared to treatment by bPEI/ dual-specific TK gene alone or 
bevacizumab alone (Fig. 5). These results show that combina-
tion therapy of bPEI/dual-specific TK gene with bevacizumab 
can increase the anti-cancer efficacy of gene therapy in malig-
nant glioma of the spinal cord. We also found that even an in-
jection of bPEI/dual-specific TK gene complexes alone or 
bevacizumab alone reduced the tumor area compared to the 
untreated control group (Fig. 5C). Bevacizumab is an FDA-
approved drug with an anti-angiogenesis effect. It also has the 
effect of inhibition angiogenesis in tumors, thereby inhibiting 
tumor growth and causing hypoxia condition. As a result, it in-
creases the effect of the dual-specific TK gene, although hypox-
ia condition induces VEGF expression. 
The dual-specific TK gene increased the apoptosis of C6 gli-
oma cells and reduced the side effects produced by tissue-spe-
cific promoters.33 Gene therapy using the HSV-TK suicide gene 
is a promising approach to treat tumors in the CNS.34 Howev-
er, it also induces non-specific cell death near the tumor tissue. 
Many studies have reported the ability of tissue-specific genes 
to reduce such side effects and enhance the effects of thera-
peutic genes.35 Oh, et al.16 reported that complexes of R7L10 
peptide/glioblastoma-specific TK gene with bevacizumab in-
creased the therapeutic effect of the HSV-TK gene on glioblas-
toma in the brain. Also, these complexes using a low dose of 
PEI did not show tissue damage after intravenous injection. The 
tissue-specific GFAP promoter (gfa2) has been shown to reduce 
the side effects of gene therapy and increase its specificity.36 
The insertion of an Epo enhancer upstream of the tissue-spe-
cific promoter increases the expression of the TK gene under 
hypoxic conditions, resulting in a dual-specific gene expres-
sion system.12 In this study, the hypoxia/glioma dual-specific 
gene expression system efficiently induced the expression of 
the cancer suicide gene in IMSCTs.
The present study demonstrated that a combination therapy 
using hypoxia-glioma dual-specific TK gene and bevacizumab 
resulted in better maintenance of the walking function in rat 
hind-limbs compared to using any treatment method alone 
(Fig. 4). This result may be attributed to the bevacizumab-in-
duced inhibition of angiogenesis and development of a hy-
poxia-like condition in the tumors. These results also led to an 
increase in the expression of the hypoxia-glioma dual-specific 
TK gene and apoptosis of tumor cells. Anti-angiogenic thera-
py combined with chemotherapy offers several potential ad-
vantages over conventional chemotherapy.37,38 Bevacizumab, 
an anti-angiogenic agent, targets VEGF and inhibits its expres-
sion in tumors.39,40 Therefore, its use has been found to prevent 
angiogenesis, an effect that inhibits the growth of spinal cord 
tumors.4 Bevacizumab also reduces the side effects by limiting 
the amount and need for other chemotherapy or therapeutic 
genes.16
For the long-term study of spinal cord tumors, it is neces-
sary that the combination therapy using both dual-specific TK 
gene and bevacizumab promotes the survival of the animals 
studied. A limitation of the present study was the use of C6 gli-
oma cells of rats. Repeating the same experiments with a human 
tumor cell line will provide a better perspective. In this study, we 
demonstrated that the efficacy of dual-specific TK gene in the 
treatment of spinal cord tumor may be enhanced when com-
bined with a bevacizumab injection. The combination treat-
ment significantly reduced the tumor mass in the spinal cord 
and enhanced the walking function of the rat hind-limbs. 
These results suggest that the combination therapy using du-
al-specific TK gene and bevacizumab offers great potential for 
the treatment of spinal cord tumor.
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